Management ChangeMay 18, 2026, 08:02 AM
Kyverna Names Greg Martini CFO; Grants 325,000 Stock Options
AI Summary
Kyverna Therapeutics, Inc. announced the appointment of Gregory Martini as its new Chief Financial Officer, effective May 18, 2026. Martini, who previously served as CFO of Ironwood Pharmaceuticals, will oversee Kyverna's financial strategy and operations as the company prepares for the potential commercialization of its lead therapy, miv-cel. His compensation package includes an annual salary of $525,000, a $300,000 sign-on bonus, and an option to purchase 325,000 shares of common stock.
Key Highlights
- Gregory Martini appointed Chief Financial Officer, effective May 18, 2026.
- Martini previously served as CFO of Ironwood Pharmaceuticals Inc.
- His initial annualized base salary is set at $525,000.
- He is eligible for an annual performance bonus of 40% of his base salary.
- Martini will receive a sign-on bonus totaling $300,000.
- He was granted an option to purchase 325,000 shares of common stock.
- The equity option vests over four years, with 25% on the first anniversary.
Price Impact
More from KYTX